Arcutis Corp (ARQT) - מקדם חוב לטווח ארוך להון

Arcutis Biotherapeutics (ARQT) is developing a distribution network for the delivery of dermatological products to minimize the risk of pharmacy disruptions. Management is focused on the expansion of an innovative non-steroidal psoriasis treatment, which is recorded at 0.52. Serving as the primary valuation tool, this price chart illustrates the asset's dynamics. Meanwhile, the business relies on external manufacturers, controlling batch quality through long-term vendor contracts.

This indicator measures the degree of financial leverage by comparing long-term borrowed funds to equity to assess the balance sheet structure's resilience to market volatility. An analysis of the long-term debt-to-equity ratio confirms the ability of Arcutis Biotherapeutics (ARQT) to fund the expansion of its sales force and the retention of key R&D specialists without a critical debt burden, which minimizes the risk of bankruptcy in the event of a sharp decline in capitalization.